A monoclonal antibody against aripiprazole complex, its preparation method and application
By developing a monoclonal antibody 2C11 that specifically binds to the aripiprazole-antibody complex, and employing a sandwich method for aripiprazole detection, the problems of insufficient sensitivity and narrow linear range in existing technologies have been solved. This has enabled aripiprazole detection with high sensitivity and a wide linear range, improving the specificity and accuracy of the detection.
Patent Information
- Application Number
- CN202611210375.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-11
- Publication Date
- 2026-11-17
AI Technical Summary
Existing aripiprazole detection methods suffer from insufficient sensitivity, narrow linear range, and poor specificity, especially competitive detection methods which are inaccurate in high-concentration samples.
A monoclonal antibody 2C11 that specifically binds to the aripiprazole-anti-aripiprazole antibody complex was developed. The sandwich detection principle was adopted, and the complex formed by the monoclonal antibody 2C11 and the aripiprazole-antibody Ab1 was used for detection, combined with signal detection systems such as enzyme-linked immunosorbent assay.
It achieves high sensitivity and wide linear range detection of aripiprazole, with the detection signal being proportional to the sample concentration, covering the clinical therapeutic window of aripiprazole, and improving the specificity and accuracy of the detection.
Smart Images

Figure CN123106913A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biological detection technology, specifically relating to a monoclonal antibody that specifically binds to an aripiprazole-anti-aripiprazole antibody complex, its preparation method, and its application in establishing an aripiprazole sandwich assay reagent. Background Technology
[0002] Aripiprazole is a second-generation atypical antipsychotic drug, belonging to the quinolinone class of compounds, and was the first dopamine D2 receptor partial agonist approved for clinical use. It is effective for both positive and negative symptoms of schizophrenia and can reduce relapse rates. However, adverse drug reactions to aripiprazole are relatively common, and its pharmacokinetics vary greatly among individuals, with plasma concentrations differing by 4-10 times at the same dose. Aripiprazole requires plasma concentrations of at least 100 ng / mL to produce a clinical effect, with its optimal therapeutic window being 150–300 ng / mL. Therefore, monitoring aripiprazole plasma concentrations is recommended by the Agonistan General Practice (AGNP) guidelines for neuropsychopharmacology as a clinically valuable method.
[0003] Currently, the commonly used detection methods for aripiprazole include gas chromatography (GC), gas chromatography-mass spectrometry (GC-MS), high performance liquid chromatography (HPLC), and liquid chromatography-mass spectrometry (LC-MS). Although these instrumental analytical methods have extremely high sensitivity and precision, they require expensive equipment, professional operators, and complex sample pretreatment, making them unsuitable for rapid screening of batches of samples and on-site real-time detection.
[0004] Immunoassay has become an important development direction for small molecule drug detection due to its advantages such as simplicity, efficiency, sensitivity, and suitability for high-throughput detection. However, aripiprazole is a small molecule compound (molecular weight approximately 448 Da), typically with only one antigenic epitope, making it difficult for two antibodies to simultaneously bind and form a "sandwich" structure. Therefore, existing aripiprazole immunoassay reagents all employ a competitive assay principle: aripiprazole in the sample competes with labeled aripiprazole for binding to a limited amount of antibody, and the analyte concentration is indirectly inferred by detecting the intensity of the labeled signal. This method has inherent drawbacks: ① the detection signal is inversely proportional to the sample concentration, leading to inaccurate detection of high-concentration samples; ② the detection linear range is usually narrow; ③ the sensitivity is relatively insufficient.
[0005] Therefore, developing a raw material and method for sandwich detection of small molecule aripiprazole to overcome the problems of insufficient sensitivity, narrow detection range, and poor specificity of existing competing reagents is of great practical significance. Summary of the Invention
[0006] Technical problems to be solved This invention aims to provide a monoclonal antibody against aripiprazole complexes, its preparation method, and its application, in order to solve the technical problems of insufficient sensitivity, narrow detection linear range, and poor specificity of existing small molecule aripiprazole competitive detection reagents, and to provide a novel sandwich method-based solution for rapid and accurate detection of aripiprazole.
[0007] Technical solution In a first aspect, the present invention provides a monoclonal antibody or antigen-binding fragment thereof that specifically binds to an aripiprazole-anti-aripiprazole antibody complex, wherein the amino acid sequences of its heavy chain complementarity-determining regions CDR1, CDR2 and CDR3 are shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively; and the amino acid sequences of its light chain complementarity-determining regions CDR1, CDR2 and CDR3 are shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively.
[0008] The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:8.
[0009] The monoclonal antibody comprises a heavy chain and a light chain, the amino acid sequence of which is shown in SEQ ID NO:9 and the amino acid sequence of which is shown in SEQ ID NO:10.
[0010] In this invention, the "aripiprazole-anti-aripiprazole antibody complex" refers to a complex formed by the specific binding of aripiprazole and anti-aripiprazole antibody Ab1 via antigen-antibody specificity. The epitope recognized by the monoclonal antibody of this invention is a newly formed epitope after aripiprazole binds to Ab1 (including complex interface epitopes or binding-induced conformational epitopes), which is not present in free Ab1 or free aripiprazole. The antigen-binding fragments include, but are not limited to, Fab, Fab', F(ab')2, and scFv.
[0011] The present invention also provides an isolated nucleic acid encoding the above-mentioned monoclonal antibody or its antigen-binding fragment, a vector containing the nucleic acid, a host cell containing the nucleic acid or the vector, and a hybridoma cell line secreting the above-mentioned monoclonal antibody.
[0012] A second aspect of the present invention provides a method for preparing the above-mentioned monoclonal antibody or its antigen-binding fragment, comprising the following steps: S1: Use the complex formed by aripiprazole or an aripiprazole derivative and anti-aripiprazole antibody Ab1 as an immunogen to immunize animals; S2: Fuse spleen cells from immunized animals with myeloma cells; S3: Screen for hybridoma cells that can specifically recognize the complex but not the free anti-aripiperazole antibody Ab1; S4: Culture the selected hybridoma cells and purify the monoclonal antibody or its antigen-binding fragment from the culture supernatant or animal ascites.
[0013] The anti-aripiperazole antibody Ab1 is an antibody that can specifically bind to aripiprazole and form a new epitope that can be recognized by the monoclonal antibody of the present invention after binding. It is preferably the same antibody clone used to prepare the immunogen (such as ACT-mAb-APZ-001) or an equivalent antibody with the same CDR sequence.
[0014] A third aspect of the present invention provides a sandwich assay kit for detecting aripiprazole, comprising: The first antibody is anti-aripiperazole antibody Ab1; The second antibody is the monoclonal antibody or its antigen-binding fragment described above; And a signal detection system for detecting a sandwich complex formed by aripiprazole, a primary antibody, and a secondary antibody.
[0015] The signal detection system can employ commonly used immunoassay signal systems in the field, including but not limited to fluorescence immunochromatography, enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (such as magnetic microparticle chemiluminescence), colloidal gold immunochromatography, or time-resolved fluorescence immunoassay; the second antibody can be coated on a solid support (such as a nitrocellulose membrane, magnetic microparticles, or an ELISA plate) as a capture antibody, and the first antibody can be labeled with a detectable signal marker (such as fluorescent microspheres, enzymes, chemiluminescent agents, or colloidal gold) as a detection antibody.
[0016] A fourth aspect of the present invention provides a method for detecting aripiprazole for non-diagnostic purposes, comprising: The sample to be tested is incubated with anti-aripiperazole antibody Ab1 and the monoclonal antibody or its antigen-binding fragment to form a sandwich complex of "monoclonal antibody-aripiperazole-Ab1". The content of aripiprazole in the sample to be tested is determined by detecting the detectable signal on the sandwich complex.
[0017] In a fifth aspect, the invention provides the use of the above-described monoclonal antibody or its antigen-binding fragment in the preparation of reagents or kits for sandwich detection of aripiprazole.
[0018] Beneficial effects Compared with the prior art, the present invention has the following significant advantages: For the first time, a specific monoclonal antibody 2C11 targeting the "aripiprazole-anti-aripiprazole antibody complex" was provided, successfully enabling the sandwich method detection of the small molecule drug aripiprazole.
[0019] The sandwich reagent established using the antibody of this invention has a detection signal that is directly proportional to the concentration of aripiprazole in the sample, fundamentally solving the problem of inaccurate detection of high-concentration samples in competitive methods.
[0020] Compared to traditional competitive methods, the sandwich method detection reagent established in this invention has higher sensitivity and a wider linear detection range. Experiments show that the reagent exhibits good linearity within the clinical sample concentration range of 4.68-480.42 ng / mL, fully covering the clinical therapeutic window of aripiprazole, and has extremely high application value.
[0021] The monoclonal antibody 2C11 of this invention has extremely high specificity, recognizing only the complex of aripiprazole and Ab1, and hardly binding to free Ab1 or aripiprazole, effectively reducing background interference and improving the specificity and accuracy of detection. Attached Figure Description
[0022] Figure 1 This is an SDS-PAGE electrophoresis image of the purified monoclonal antibody 2C11 in Example 1 of this invention.
[0023] Figure 2 The image shows the results of detecting the binding activity of monoclonal antibody 2C11 by indirect ELISA in Example 2 of the present invention, indicating that it specifically recognizes the aripiprazole-Ab1 complex.
[0024] Figure 3 This is a linear graph showing the detection of aripiprazole immunofluorescence sandwich assay reagent established using monoclonal antibody 2C11 in Example 3 of this invention, and its application to a series of clinical samples at different concentrations.
[0025] Figure 4 This is a flowchart of the preparation process of aripiprazole hapten. Detailed Implementation
[0026] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to the accompanying drawings and specific embodiments. However, it should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention.
[0027] Example 1: Preparation of anti-aripiperazole complex monoclonal antibody 2C11 The reagents or kits used in this example were sourced from the following sources: Freund's complete adjuvant (Catalog No. 77140, Thermo Fisher); Freund's incomplete adjuvant (Catalog No. 77145, Thermo Fisher); HAT Media Supplement (50×) (Catalog No. 21060017, Thermo Fisher); HT Media Supplement (50×) (Catalog No. H0111067030, Thermo Fisher); PEG (Catalog No. P7181, Sigma); RPMI 1640 culture medium (Catalog No. L210KJ, Shanghai Yuanpei Biotechnology); Fetal bovine serum (FBS) (Catalog No. C04001-500, Shanghai Xiaopeng Biotechnology); DMEM (Catalog No. L310KJ, Shanghai Yuanpei Biotechnology); Penicillin-streptomycin (Catalog No. 15140122, Gibco); HRP-labeled goat anti-mouse antibody (Catalog No. D110087, Shanghai Sangon Biotech); Protein A Resin (Catalog No. SA023010, Changzhou Tiandi Renhe Biotechnology Co., Ltd.); Aripiprazole (Catalog No. A124880-1g, Aladdin); Anti-aripiprazole antibody Ab1 (Catalog No. ACT-mAb-APZ-001, Changzhou Zhongmei Xinxin Biotechnology Co., Ltd.).
[0028] 1. Preparation of immunogens (1) Take 1000 mg of aripiprazole (purchased from Aladdin, catalog number A124880-1g) and 5 mL of methanol, stir to dissolve, add to a 25 mL three-necked flask, and slowly add concentrated sulfuric acid (375 mg) dropwise while controlling the temperature in the range of 5-15℃. Then raise the temperature to 40-45℃ and react at this temperature for 2 hours. After the reaction is completed, add 15 mL of water, cool to 5-10℃, adjust the pH to 8.5 with sodium hydroxide, add 10 mL of ethyl acetate, stir for 20 minutes, and let stand to separate the layers to obtain the organic layer (i.e., the ethyl acetate solution of substance A in the flow chart).
[0029] The organic layer was concentrated under reduced pressure to remove ethyl acetate, and then 12 mL of water was added. The pH was adjusted to 12 with sodium hydroxide, and the reaction was carried out at room temperature for 30 minutes. Then, 8 mL of ethyl acetate was added, and the pH was adjusted to 4.5 with dilute sulfuric acid. The mixture was stirred for 20 minutes and allowed to stand to separate into layers, yielding the organic layer. 100 mL of dichloromethane was added to the organic layer, and the mixture was cooled to 0-5 °C and stirred to crystallize for 2 hours. After filtration, 0.75 g of activated aripiprazole hapten was obtained.
[0030] Take anti-aripiperazole antibody Ab1 and slowly add the activated aripiprazole hapten dropwise to the Ab1 antibody solution at an antibody-to-activated hapten ratio of 1:24. React overnight at 4°C. After the reaction, repeatedly centrifuge through an ultrafiltration concentrator (molecular weight cutoff 50 kDa) to remove unreacted free aripiprazole hapten and organic solvent, thus obtaining the immunogen-"aripiperazole-Ab1" complex.
[0031] 2. Mouse immunization The above immunogen solution was emulsified with an equal volume of Freund's complete adjuvant and administered subcutaneously at multiple sites to 6-8 week old SPF-grade Balb / c mice (purchased from Fuzhou Wu's Animal Experiment Center) at a dose of 200 μg / mouse. Two weeks later, booster immunizations were administered with an immunogen emulsified with an equal volume of Freund's incomplete adjuvant at a dose of 100 μg / mouse, for a total of two booster immunizations. Three days before fusion, an intraperitoneal pulse immunization was performed, injecting 100 μg / mouse of adjuvant-free immunogen.
[0032] 3. Cell fusion and hybridoma screening (1) Preparation of feeder cells: One day before fusion, Balb / c mice were euthanized by cervical dislocation, and peritoneal macrophages were collected. The cells were washed with RPMI 1640 basal culture medium containing 1% (v / v) penicillin-streptomycin, centrifuged to collect the cells, and resuspended in RPMI 1640 complete culture medium containing 10% (v / v) fetal bovine serum and 1×HAT, and the concentration was adjusted to 1×10⁻⁶. 5 Cells / mL, seeded into 96-well plates, 150 μL / well, and incubated overnight at 37°C in a 5% CO2 incubator.
[0033] (2) Preparation of immune spleen cells: Three days after the last immunization of the mice, the spleen was removed under sterile conditions, placed in a petri dish, rinsed once with RPMI 1640 basal culture medium, ground and filtered on a nylon mesh (the nylon mesh was placed in a small beaker) to prepare a cell suspension. Centrifuge, discard the supernatant, resuspend in RPMI 1640 basal culture medium, repeat this process three times, and count the cells.
[0034] (3) Fusion: Take 40 mL of HAT culture medium, 15 mL of DMEM serum-free culture medium (Shanghai Yuanpei Biotechnology, catalog number: L310KJ) and 1 mL of 50% PEG (M12000, Sigma, catalog number: P7181) and place them in a 37°C water bath for preheating; Take mouse myeloma cell Sp2 / 0 suspensions (2 × 10⁷ cells) and the above-mentioned immune spleen cells (1 × 10⁸ cells) and add them to a 50 mL centrifuge tube, mix well, and add DMEM serum-free culture medium to a final volume of 40 mL. Centrifuge for 10 minutes, discard the supernatant, and mix well. Place the centrifuge tube in pre-warmed water at 37°C, take 0.7 mL of pre-warmed 50% PEG solution at 37°C, and let it stand for 90 seconds. Immediately add 15 mL of pre-warmed serum-free culture medium at 37°C; Add DMEM serum-free culture medium to a final volume of 40 mL, centrifuge for 10 minutes, and discard the supernatant. Add 40 mL of HAT culture medium containing 15%-20% fetal bovine serum (FBS). Mix well with a pipette and add 2 drops to each well of a 96-well cell culture plate containing feeder cells. Incubate at 37°C with 7% CO2. Fetal bovine serum: Shanghai Xiaopeng Biotechnology, catalog number: C04001-500.
[0035] (4) Screening and Cloning: On days 1, 3, 5, and 7 after cell fusion, the culture medium was changed with HAT medium containing 15%-20% fetal bovine serum. The surviving cells were hybridoma cells, while the non-hybridoma cells died. True hybridoma cells were selected. The supernatant of each culture well was aspirated, and the culture medium containing culture wells that specifically recognized the aripiprazole antibody and the small molecule aripiprazole complex, but not the aripiprazole antibody, was detected by indirect ELISA. Antibody cell lines with an OD450 difference greater than 1.5 between the ELISA for recognizing the complex and the single antibody were screened. The day before cloning, feeder cells were prepared and plated according to step 3. The above antibody cell lines with good reactivity were mixed by pipetting, and the cells in each well were diluted with HT medium to 1 cell per well. The cells were then humidified at 37°C and 5% CO2 for 7 days. After 10 days, the appearance of visible clones allows for antibody detection. Under an inverted microscope, wells with only a single clone growing are marked, and the monoclonal antibody hybridoma cell line 2C11 is obtained through preliminary screening.
[0036] 4. Antibody sequencing Total RNA was extracted from hybridoma cell line 2C11, and the heavy and light chain genes of the antibody were amplified by RT-PCR and sequenced. The sequencing results showed that the amino acid sequence of the monoclonal antibody 2C11 is as follows: Heavy chain CDR1: THKQWF (SEQ ID NO:1) Heavy chain CDR2: GAFVEMNRCY (SEQ ID NO:2) Heavy chain CDR3: WPLSNQYCH (SEQ ID NO:3) Light chain CDR1: ERTMVAIDG (SEQ ID NO:4) Light chain CDR2: YKCSLHWTPE (SEQ ID NO:5) Light chain CDR3: QNFGDRIA (SEQ ID NO:6) Heavy chain variable region sequence: QVQLQQPAAELVRPGASVKMSCKASGYNFTHKQWFWVKQRPGRGLEWIGGAFVEMNRCYKATLTVDKSSSTAYIQLSGLASEDSAVYYCTRWPLSNQYCHWGQGTTLTVSS (SEQ ID NO:7) Light chain variable region sequence: DIVMTQSTSSLSVSLGDRVTITCERTMVAIDGWYQQKPDGTVKLLIYYKCSLHWTPEVPSRFSASGSGTDYSLTISNLEQEDFATYFCQNFGDRIAFGGGTKLEIK (SEQ ID NO:8) Whole antibody heavy chain sequence: QVQLQQPAAELVRPGASVKMSCKASGYNFTHKQWFWVKQRPGRGLEWIGGAFVEMNRCYKATLTVDKSSSTAYIQLSGLASEDSAVYYCTRWPLSNQYCHWGQGTTLTVSSSTPPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMVTDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKLRVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK (SEQ ID NO:9) Full-length antibody light chain sequence: DIVMTQSTSSLSVSLGDRVTITCERTMVAIDGWYQQKPDGTVKLLIYYKCSLHWTPEVPSRFSASGSGTDYSLTISNLEQEDFATYFCQNFGDRIAFGGGTKLEIK RTDAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC (SEQ IDNO:10) 5. Antibody production and purification Balb / c mice were injected intraperitoneally with 0.5 mL of liquid paraffin, and 10 days later, 1×10⁻⁶ g of the paraffin was added to the paraffin solution. 6 Hybridoma cells 2C11 were inoculated into the peritoneal cavity of mice. Approximately 10 days later, ascites fluid was collected, and the supernatant was obtained by centrifugation. Purification was performed using a Protein A affinity chromatography column, following the Cytiva manual, to obtain the high-purity monoclonal antibody 2C11. The purification results are shown below. Figure 1 SDS-PAGE showed that the heavy and light chain bands were clear and uniform, indicating high purity.
[0037] Example 2: Detection of the activity and specificity of antibody 2C11 by ELISA Coating: The microplate was coated with 100 ng / well of aripiprazole antibody Ab1 and a mixture of 100 ng Ab1 and 10 ng aripiprazole (10 mM phosphate buffer, pH 7.4) and incubated overnight at 2-8°C.
[0038] Washing and blocking: Discard the coating solution and wash the plate once with washing buffer (20 mM phosphate-buffered saline containing 0.05% Tween 20). Add 200 μL of blocking buffer (containing 10% skim milk) to each well and block at room temperature for 1 hour.
[0039] Add primary antibody: Discard the blocking buffer, add 100 μL of serially diluted 2C11 antibody solution to each well, and incubate at room temperature for 1 hour. Wash 6 times.
[0040] Add enzyme-labeled secondary antibody: Add 100 μL of HRP-labeled goat anti-mouse antibody diluted 1:10000 to each well and incubate at 37°C for 30 minutes. Wash 6 times.
[0041] Color development and reading: Add 100 μL of freshly prepared substrate solution to each well and incubate at 37°C in the dark for 15 minutes. Stop the reaction by adding 50 μL of 2 mol / L H₂SO₄ and read the OD450 value. Results are shown in the attached instructions. Figure 2As shown in Table 1, the 2C11 antibody hardly binds to free Ab1, maintaining an extremely low OD450 value; however, the binding signal of the complex formed by 2C11 and Ab1 + aripiprazole increases linearly with increasing antibody concentration, indicating good binding activity. This fully demonstrates that the 2C11 antibody can specifically recognize and bind with high affinity to the aripiprazole-Ab1 complex conformation, without binding to Ab1 alone.
[0042] Table 1. ELISA of 2C11 with aripiprazole antibody Ab1 + aripiprazole complex
[0043] Example 3: Application of monoclonal antibody 2C11 in the detection of aripiprazole using immunofluorescence sandwich assay Preparation of reagent strips: Coated T line: The purified aripiprazole complex antibody 2C11 was streaked onto a nitrocellulose membrane (NC membrane) at a concentration of 0.2 μg / cm to serve as the detection line (T line).
[0044] Coating C line: Aripiprazole-BSA conjugate (catalog number ACT-Ag-APZ-001, Changzhou Zhongmei Xinxin) was streaked onto the same NC membrane at a dosage of 0.4 μg / cm as the quality control line (C line).
[0045] The NC membrane was dried at 55°C for 5 days.
[0046] Preparation of conjugate pads: Anti-aripiperazole antibody Ab1 was labeled with fluorescent microspheres and sprayed onto glass fiber conjugate pads at a protein concentration of 0.05 μg Ab1 / cm. The pads were then vacuum dried for 3 hours.
[0047] Assembly: The sample pad, conjugate pad, NC film coated with T / C lines, and absorbent pad are sequentially pasted onto the PVC base plate, cut into strips, and assembled into test strips.
[0048] Sample testing: Clinical serum samples of aripiprazole at known concentrations (hospital LC-MS-assigned samples), ranging from 4.68 to 480.42 ng / mL, were added to the sample pad of the test strip. The reaction was allowed to proceed for 15 minutes at room temperature and humidity. The test strip was then placed in a fluorescence detector, and the fluorescence signals of the T and C lines were read. The T / C ratio was calculated. Results are as follows: Figure 3 As shown in Table 2 below: The T / C fluorescence signal value increased proportionally with the increase of aripiprazole concentration in the sample, exhibiting a good linear relationship within the range of 4.68-480.42 ng / mL. R²>0.98). This linear range fully covers the clinical therapeutic window of aripiprazole (150-300 ng / mL) and has high sensitivity to low concentration samples, solving the problems of high-concentration "HOOK effect" and narrow linear range commonly found in competitive reagents.
[0049] Table 2. Clinical detection results of aripiprazole using the immunofluorescence sandwich method.
[0050] The above description is merely a preferred embodiment of the present invention and is not intended to limit the invention. Various modifications and variations can be made to the invention by those skilled in the art. Any modifications, equivalent substitutions, or improvements made within the spirit and principles of the invention should be included within the scope of protection of the invention.
Claims
1. A monoclonal antibody or its antigen-binding fragment that specifically binds to an aripiprazole-anti-aripiprazole antibody complex, characterized in that, The amino acid sequences of its heavy chain complementarity-determining regions CDR1, CDR2 and CDR3 are shown in SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3, respectively; the amino acid sequences of its light chain complementarity-determining regions CDR1, CDR2 and CDR3 are shown in SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6, respectively.
2. The monoclonal antibody or its antigen-binding fragment according to claim 1, characterized in that, The amino acid sequence of the heavy chain variable region of the antibody is shown in SEQ ID NO:7, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO:
8.
3. The monoclonal antibody according to claim 1 or 2, characterized in that, The monoclonal antibody comprises a heavy chain and a light chain, the amino acid sequence of the heavy chain being shown in SEQ ID NO:9, and the amino acid sequence of the light chain being shown in SEQ ID NO:
10.
4. An isolated nucleic acid, characterized in that, The nucleic acid encodes the monoclonal antibody or its antigen-binding fragment as described in any one of claims 1-3.
5. A method for preparing the monoclonal antibody or its antigen-binding fragment according to any one of claims 1-3, characterized in that, Includes the following steps: S1: Immunize animals with a complex formed by aripiprazole or an aripiprazole derivative and anti-aripiprazole antibody Ab1 as an immunogen; S2: Spleen cells from immunized animals are fused with myeloma cells; S3: Screen for hybridoma cells that can specifically bind to the complex without binding to free anti-aripiperazole antibody Ab1; S4: Culture the selected hybridoma cells and purify the monoclonal antibody or its antigen-binding fragment from the culture supernatant or animal ascites.
6. A sandwich assay kit for detecting aripiprazole, characterized in that, Include: a. First antibody, the first antibody being anti-aripiperazole antibody Ab1; b. A second antibody, wherein the second antibody is the monoclonal antibody or its antigen-binding fragment as described in any one of claims 1-3; c. A signal detection system for detecting a sandwich complex formed by aripiprazole, a primary antibody, and a secondary antibody.
7. The reagent kit according to claim 6, characterized in that, The second antibody is coated on a solid support as a capture antibody, and the first antibody is labeled with a detectable signal marker as a detection antibody.
8. The reagent kit according to claim 7, characterized in that, The solid support is a nitrocellulose membrane, and the detectable signal marker is a fluorescent microsphere.
9. A method for detecting aripiprazole for non-diagnostic purposes, characterized in that, include: The sample to be tested is simultaneously contacted with anti-aripiperazole antibody Ab1 and the monoclonal antibody or its antigen-binding fragment as described in any one of claims 1-3 to form a "monoclonal antibody 2C11-aripiperazole-Ab1" sandwich complex. Quantitative analysis of aripiprazole in the test sample is achieved by detecting the detectable signal on the sandwich complex.
10. The use of the monoclonal antibody or its antigen-binding fragment according to any one of claims 1-3 in the preparation of a sandwich assay reagent or kit for the detection of aripiprazole.
